Phil Deschamps | CEO |
Joyce LaViscount | CFO and COO |
Steven Lichtman | Oppenheimer |
Sean Lavin | the BTIG |
Good afternoon ladies, and gentlemen and welcome to the Fourth Quarter of Fiscal Year 2018 Earnings Conference Call for Helius Medical Technologies. At this time, all participants have been placed in a listen-only mode. Please note that this conference call is being recorded and that the recording will be available on the Company's website for replay shortly.
Before we begin, I would like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements that are based on the current expectations of management, including statements regarding the potential FDA clearance of the PoNS device, the future commercialization of the PoNS treatment, expected future clinical and regulatory timelines and projected financial results. These forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including those identified in the Risk Factors sections of our most recent Annual Report on Form 10-K filed with the SEC.